Profile
AKAN ZTS HLN TAK TEVA VTRS
Company Name Akanda Corp. Zoetis Inc. Haleon plc Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $1.97M $79.26B $42.82B $42.13B $18.71B $15.67B
Employees 0.05K 14.10K 25.41K 49.28K 37.00K 32.00K
CEO Ms. Katharyn Field Ms. Kristin C. Peck Mr. Brian James McNamara Mr. Christophe Weber Mr. Richard D. Francis Mr. Scott Andrew Smith Ph.D.
Ratings
AKAN ZTS HLN TAK TEVA VTRS
Quant Rating Score 2 3 3 3 1 3
Quant Rating Sell Neutral Neutral Neutral Strong Sell Neutral
Trading
AKAN ZTS HLN TAK TEVA VTRS
Last Close $1.37 $175.67 $9.48 $13.29 $17.03 $13.13
High 52 $4.11 $199.94 $10.69 $15.08 $18.96 $13.53
Low 52 $0.09 $145.54 $8.01 $12.6 $10.44 $10.05
Price vs. 52 Week High -66.67 % -12.14 % -11.32 % -11.87 % -10.18 % -2.96 %
Price vs. 52 Week Low 1422.22 % 20.7 % 18.35 % 5.48 % 63.12 % 30.65 %
Total Return
AKAN ZTS HLN TAK TEVA VTRS
1 Month Return 28.04 % -7.27 % -5.01 % -6.08 % -6.33 % 13.48 %
3 Month Return -4.2 % -3.95 % -3.95 % -11.04 % -6.07 % 12.03 %
6 Month Return 1373.12 % 1.67 % 11.27 % 0.68 % 2.65 % 19.8 %
9 Month Return 353.34 % -6.75 % 13.81 % -9.84 % 31 % -0.98 %
YTD Return 211.01 % -10.99 % 15.19 % -6.87 % 63.12 % 21.24 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
AKAN ZTS HLN TAK TEVA VTRS
Dividend Yield Percentage (TTM) - 0.98 % 2.11 % 4.77 % - 3.66 %
Dividend Paid and Capex Coverage Ration (TTM) -3.04 % 2.1 % - 1.29 % 5.06 % 2.39 %
Dividend Per Share (TTM) - 1.73 % 0.16 % 0.63 % - 0.48 %
Payout Ratio (TTM) - 31.44 % - 101.62 % - -65.15 %
Growth
AKAN ZTS HLN TAK TEVA VTRS
Asset Growth -77.33 % -4.28 % -2.18 % 8.25 % -1.2 % -4.67 %
Gross Profit Growth -426.32 % 3.7 % 5.85 % -16.6 % 9.64 % -0.9 %
Revenue Growth -17.55 % 5.74 % 4.09 % 5.87 % 6.16 % -5.14 %
Revenue 3 Year 67104.7 % 31.98 % 13.9 % 33.13 % -6.92 % -35.32 %
Revenue 5 Year - 53.64 % 32.87 % 149.89 % -23.33 % -41.73 %
Revenue 10 Year - 103.1 % 32.87 % 154.38 % -40.82 % -26.57 %
EBIT Growth 50.88 % 6.27 % 37.26 % 7.34 % -84.52 % -52.55 %
Net Income Growth -8228.82 % 10.88 % -1.04 % -54.56 % 76.24 % -97.37 %
Net Income 3 Yeari Growth Per Share -602.85 % 47.55 % -8.67 % -61.74 % 86.29 % 104.09 %
Net Income 5 Yeari Growth Per Share -996.44 % 71.94 % 59.66 % 62.27 % 76.28 % -93.3 %
Net Income 10 Yeari Growth Per Share -996.44 % 404.24 % 59.66 % 36.33 % -133.42 % -97.12 %
Operating Income Growth 50.88 % 6.27 % 37.26 % 7.34 % -84.52 % -52.55 %
Operating Cash Flow Growth (CFG) 86.92 % 23.06 % -16.48 % -34.47 % -13.96 % -5.18 %
Operating 3 Year CFG 28.82 % 14.12 % 22.08 % -36.76 % 10.09 % 13.84 %
Operating 5 Year CFG -49.87 % 37.69 % 118.54 % 139.61 % -48.98 % -48.37 %
Operating 10 Year CFG -49.87 % 274.61 % 118.54 % 335.67 % -67.94 % -16.8 %
EPS Growth -6609.09 % 12.64 % - -54.92 % 76.42 % -97.08 %
EPS Diluted Growth -6609.09 % 12.92 % - -54.86 % 76.42 % -97.08 %
Book Value Per Share -110.94 % 15.25 % 1.35 % 13.54 % -7.25 % -1.92 %
Share Holder 3 Year Equity Growth Per Share 51.18 % 36.7 % -36.6 % 40.38 % -26.74 % -55.34 %
Share Holder 5 Year Equity Growth Per Share - 139.55 % -39.41 % 73.27 % -53.44 % -27.35 %
Share Holder 10 Year Equity Growth Per Share - 476.36 % -39.41 % 197.1 % -74.76 % 128.81 %
Dividend Per Share Growth - 15.15 % -85.58 % 1.95 % - -0.06 %
Dividend 3 Year Growth Per Share - 87.76 % -83.69 % 1.19 % - -
Dividend 5 Year Growth Per Share - 198.29 % -66.42 % 146.94 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % -66.42 % 103.93 % -100 % -
Debt Growth 2.54 % -15.91 % -9.43 % 24.67 % -6.53 % -5.93 %
Free Cash Flow Growth 87.25 % 22.25 % -20.06 % -53.54 % -19.19 % -7.35 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023
Profitability
AKAN ZTS HLN TAK TEVA VTRS
Gross Profit Margin TTM -141.38 % 68.87 % 59.91 % 62.47 % 49.87 % 40.26 %
Return on Assets TTM -350.79 % 16.93 % 3.26 % 1.99 % -2.38 % -1.97 %
Return on Equity TTM -753.35 % 47.99 % 6.54 % 4.04 % -14.58 % -4.43 %
Return on Capital Employed TTM -271.05 % 26.64 % 7.25 % 5.27 % 7.66 % -0.71 %
Net Income Per EBT TTM 101.34 % 79.65 % 65.38 % 109.03 % 175.89 % 92.81 %
EBT Per Ebit TTM 278.48 % 90.51 % 82.66 % 41.38 % -26.34 % 359.67 %
EBIT Per Revenue TTM -469.74 % 36.83 % 17.88 % 14.14 % 12.76 % -1.76 %
Cash Flow To Debt Ratio TTM -1093.05 % 44.8 % - 17.01 % 13 % 13.05 %
Receivables Turnover TTM 8.46 6.49 5.27 6.3 4.85 3.81
Payables Turnover TTM 1.69 7.05 1.25 4.13 3.55 7.23
Inventory Turnover TTM - 1.18 3.09 1.41 2.13 2.2
Fixed Asset Turnover TTM 151.09 % 259.93 % 604.62 % 240.84 % 278.05 % 561.67 %
Asset Turnover TTM 26.46 % 63.75 % 33.71 % 31.2 % 40.19 % 33.6 %
Operating Cash Flow Per Share TTM -4.33 6.5 - 545.34 2.18 1.93
Free Cash Flow Per Share TTM -5.76 5.1 - 309.43 1.75 1.6
Cash Per Share TTM 638.87 % 378.45 % 5.72 % 57513.46 % 292.94 % 157.41 %
Operating Cash Flow Sales Ratio TTM -155.19 % 32.18 % - 18.9 % 14.71 % 15.29 %
Free Cash Flow Operating Cash Flow Ratio TTM 132.87 % 78.37 % - 56.74 % 80.23 % 83.19 %
Cash Flow Coverage Ratios TTM -1093.05 % 44.8 % - 17.01 % 13 % 13.05 %
Price To Free Cash Flows Ratio TTM -0.36 34.34 - 13.34 9.45 8.19
Price To Operating Cash Flows Ratio TTM -0.32 27.02 - 3.76 7.82 6.81
Price Cash Flow Ratio TTM -0.32 27.02 - 3.76 7.82 6.81
Income Statement (TTM)
AKAN ZTS HLN TAK TEVA VTRS
Revenue $0B $8.54B $11.3B $4263.76B $15.85B $15.43B
Gross Profit $0B $5.83B $6.96B $2321.31B $7.65B $6.44B
Gross Profit Ratio 5.16% 68.28% 61.6% 54.44% 48.25% 41.74%
EBITDA $-0.03B $3.69B $2.35B $900.33B $4.33B $3.52B
Net Income $-0.03B $2.34B $1.05B $144.07B $-0.56B $0.05B
EPS Diluted -7.16 5.07 0.11 91.16 -0.5 0.05
Balance Sheet (MRQ)
AKAN ZTS HLN TAK TEVA VTRS
Long Term Debt $0B $6.75B $8.95B $5029.93B $18.48B $16.35B
Total Liabilities $0.01B $9.3B $17.33B $7834.79B $35.35B $27.22B
Total Equity $-0B $4.99B $16.73B $7274.01B $8.13B $20.47B
Total Investments $0B $0.02B $0.07B $683.22B $0.01B $1.33B
Total Debt $0B $6.76B $9.46B $5463.39B $20.15B $18.37B
Total Assets $0.01B $14.29B $34.06B $15108.79B $43.48B $47.69B
Cash Flow Statement (TTM)
AKAN ZTS HLN TAK TEVA VTRS
Net Income $-0.03B $2.34B $1.05B $144.07B $-0.62B $0.05B
Inventory $0B $-0.36B $-0.13B $-115.74B $0B $-0.61B
Dividends Paid $0B $-0.69B $-0.39B $-287.19B $0B $-0.58B
Operating Cash Flow $-0B $2.35B $1.72B $640.32B $1.37B $2.8B
Capital Expenditure $-0B $-0.73B $-0.34B $-480.73B $-0.53B $-0.47B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.24
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 12.42
ALVOW Alvotech 3.4
AMPH Amphastar Pharmaceuticals, Inc. 43.945
AMRX Amneal Pharmaceuticals, Inc. 8.4
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 55.415
AQST Aquestive Therapeutics, Inc. 4.535
ASRT Assertio Holdings, Inc. 0.9314
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 10.73
AYTU Aytu BioPharma, Inc. 1.5103
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to AKAN
Ticker ETF Name Weight Percentage Price
MJ ETFMG Alternative Harvest ETF 0 2.575
Unlock